IDWeek 2014: HIV/HCV Coinfected People Do Not Have Poorer CD4 Cell Recovery

Among HIV positive people on suppressive antiretroviral therapy (ART), hepatitis C virus (HCV) coinfection was not associated with significantly lower CD4 T-cell or B-cell gains, according to study findings presented at IDWeek 2014 last week in Philadelphia.

Read more:

Tenofovir Usually Suppresses Hepatitis B in HIV/HBV Coinfected People

Tenofovir led to undetectable hepatitis B virus (HBV) levels in 87% of HIV positive coinfected individuals, and a similar proportion maintained viral suppression over 6 years, according to a study described in the June 20 advance edition of Hepatology.

Read more:

AIDS 2014: HIV/HCV Coinfected Have High Cure Rates with Interferon-free Hep C Combos

Two studies presented at the 20thInternational AIDS Conference this week in Melbourne showed that all-oral regimens of direct-acting antiviral agents for hepatitis C are safe and effective for HIV positive people. Both regimens demonstrated sustained virological response rates similar to those seen in people with HCV alone.

-- Sofosbuvir + Ribavirin Cures More Than 80% of HIV/HCV Coinfected People

-- AbbVie 3D Regimen Cures Most Genotype 1 HIV/HCV Coinfected Patients

Read more:

DDW 2014: Outcomes in HBV/HCV Coinfected People Depend on Which Virus Dominates

Among HBV/HCV coinfected people, about half have dominant hepatitis B virus while half have dominant hepatitis C, and those with active HBV replication are at higher risk of liver-related complications and death, according to study findings presented at Digestive Disease Week this month in Chicago.

Read more:

AIDS 2014: AbbVie 3D Regimen Cures Most Genotype 1 HIV/HCV Coinfected Patients

An all-oral regimen of 3 direct-acting antivirals plus ribavirin taken for 12 weeks demonstrated a sustained virological response rate of 94% for people coinfected with HIV and genotype 1 hepatitis C in the TURQUOISE-I study, according to a late-breaking report at the 20th International AIDS Conference (AIDS 2014) this week in Melbourne, Australia.

Read more:

Antiretroviral Therapy Reduces Liver Decompensation Risk in HIV/HCV Coinfected Patients

HIV positive people with hepatitis C coinfection who start combination antiretroviral therapy (ART) are less likely to develop decompensated liver disease, or liver failure, according to a study published in the March 1, 2014, edition of Clinical Infectious Diseases. These findings offer further support for early ART initiation for people with viral hepatitis.

Read more:

AIDS 2014: Sofosbuvir + Ribavirin Cures More Than 80% of HIV/HCV Coinfected People

An interferon-free regimen of sofosbuvir (Sovaldi) plus ribavirin for 24 weeks led to sustained virological response in 84% to 89% of HIV positive chronic hepatitis C patients with HCV genotypes 1, 2, 3, or 4, according to results from the PHOTON-2 study presented at the 20th International AIDS Conference in Melbourne, Australia. Cure rates were lower, however, for genotype 1a patients with liver cirrhosis.

Read more:

Antiretrovirals Reduce Liver Decompensation in HIV/HCV Coinfected

Starting antiretroviral therapy (ART) reduces the likelihood that HIV positive people coinfected with hepatitis C virus (HCV) will develop decompensated liver disease, according to a report published in the November 27, 2013, advance edition of Clinical Infectious Diseases.

Read more: